SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

HIDALGO TALLON, F. J.. Fibromialgia: Un trastorno de estrés oxidativo. Rev. Soc. Esp. Dolor [online]. 2012, vol.19, n.2, pp.95-100. ISSN 1134-8046.

    1. Grant JT. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol 2003;17:547-61. [ Links ]

    2. Wolfe F, Ross K, Anderson J, Russell J, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28. [ Links ]

    3. Editorial. Rev Soc Esp Dolor 2009;16(7):417-8. [ Links ]

    4. Van Houdenhove B, Egle UT. Fibromyalgia: A stress disorder? Psychotherapy and psychosomatics 2004; 73(5):267-75. [ Links ]

    5. Van Houdenhove B, Luyten P, Egle UT. Stress as a key concept in chronic widespread pain and fatigue disorders. Journal of musculosk pain 2009;17(4):390-9. [ Links ]

    6. Arnold LA, Leon T, Whalen E, Barret J. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabaline in fibromialgia 2010. Psichosomatics 51:6. [ Links ]

    7. Walker EA, Keegan D, Gardner G, Sullivan M, Katon WJ, Bernstein D. Psychological factors in fibromyalgia compared with rheumatoid artritis: I. Psychiatric diagnosisand functional disability. Psychosomatic Medicine 1997;59:565-71. [ Links ]

    8. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is acompained with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Human Psychopharmacol: Clinical and Experimental 2007;22(2):67-73. [ Links ]

    9. Felicity NG, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J of Neorupsychopharmacology 2008;11:851-76. [ Links ]

    10. Pongratz D, Spath M. Fibromyalgie. Fortschr Neurol Psychiatr 2001;69(4):189-93. [ Links ]

    11. Majid A. The cause of fibromyalgia: the respiratory-to-fermentative shift (the dysox state) in ATP production. J Integrative Medicine 2003;8:135-40. [ Links ]

    12. Reid MB. Free radicals and muscle fatigue: Of ROS, canaries, and the IOC. Free radical biology and and medicine 2008;44(2):169-79. [ Links ]

    13. Pall ML. Common etiology of posttraumatic stress disorder, fibromialgia, chronic fatigue síndrome and multiple sensitivity via elevated nitric oxide/peroxynitrite. Medical hipotheses 2001;57(2):139-45. [ Links ]

    14. Kennedy G, Khan F, Hill A, Underwood C, Belch JJ. Biochemical and vascular aspects of pediatric chronic fatigue syndrome. Arch pediatr adolesc med 2010;164(9):817-23. [ Links ]

    15. Bagge E, Bengtsson BA, Carlsson L, Carlsson J. Low growth hormone secretion in patients with fibromyalgia. A preliminary report on 10 patients and 10 controls. J Rheumatol 1998;25:145-8. [ Links ]

    16. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain treshold, and fibromyalgia symtoms in the general population. J Rheumatol 1997;24(3):555-9. [ Links ]

    17. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K. FERUM amino acids in fibrositis/fibromyalgia síndrome. J Rheumatol 1989;16:158-63. [ Links ]

    18. Bagis S, Tamer L , Sahin G, Bilgin R, Guler H, Ercan, et al. Free radicals and antioxidants in primary fibromyalgia: An oxidative stress disorder? Rheumatol Int 2005;25(3):188-90. [ Links ]

    19. Gao X, Kim HK, Chung JM, Chung K. Reactive oxygen species (ROS) are involved in enhancement of NMDA-receptor phosphorilation in animal models of pain. Pain 2007;131(3):262-71. [ Links ]

    20. Schwartz ES, Kim HY, Wang J, Lee I, Klann E, Chung JM, et al. Persistent pain is dependen ton spinal mitocondrial antioxidant levels. J Neurosci 2009;29(1):159-68. [ Links ]

    21. Eisinger J, Gandolfo C, Zakarian H, Ayavou T. Reactive oxygen species, antioxidant status and fibromyalgia. Journal of Musculoskeletal Pain 1997;5(4):5-15. [ Links ]

    22. Hein G, Franke S. Are advanced glycation end-product-modified proteins of pathogenic importance in fibromialgia? Rheumatology 2002;41:1163-7. [ Links ]

    23. Bagis S, Tamer L, Sahin G, Bilgin R, Guler H, Ercan B, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int. 2003;20. [ Links ]

    24. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromialgia: etiologic and therapeutic concerns. Rheumatol Int 2006;26:598-603. [ Links ]

    25. Lund N, Bengtsson A, Thorborg P. Muscle tissue oxygen pressure primary fibromyalgia. Scand J Rheumatol 1986;15:165-73. [ Links ]

    26. Henriksson KG. Muscle pain in neuromuscular disorders and primary fibromyalgia. European Journal of Applied Physiology and Occupational Physiology 1988;57(3):348-52. [ Links ]

    27. Bengtsson A and Henriksson KG. The muscle in fibromyalgia. A review of Swedish studies. J Rheumatol 1989;16(Supl. 19):144-9. [ Links ]

    28. Morf S, Amann-Vesti B, Forster A, Franzeck U, Koppensteiner R, Uebelhart D and Sprott H. Microcirculation abnormalities in patients with fibromialgia measured by capillary microscopy and laser fluxmetry. Arthritis Res Ther 2005;7:R209-R216. [ Links ]

    29. Mclver KL, Evans C, Kraus RM, Ispas L, Sciotti VM, Hickner RC. NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain 2006;120(1):161-9. [ Links ]

    1. Ajamieh H, Merino N, Candelario-Jali E, Menéndez S, Martínez G, Re L, et al. Similar protective effect of ischemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. Pharmacological Research 2002;45(4):333-9. [ Links ]

    2. Ajamieh HH, Menéndez S, Martínez-Sánchez G, Candelario-Jalil E, Re L, Giuliani A, et al. Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusión. Liver International 2004;24:55-62. [ Links ]

    3. Ajamieh H, Berlanga J, Merino N, Sánchez GM, Carmona AM, Cepero SM, et al. Role of protein synthesis in the protection conferred by ozone-oxidative-preconditioning in hepatic ischaemia/reperfusión. Transplant International 2005;18 (5):604-2. [ Links ]

    4. Badía X, Muriel C, Gracia A, Núñez-Olarte JM, et al. Validation of the spanish version of the Brief Pain Inventory in patients with oncological pain. Med Clin 2003;120:52-9. [ Links ]

    5. Bocci V. Ozonization of blood for the therapy of viral diseases and inmunodeficiencies. A hipothesis. Medical Hipothesis 1992;39:30-4. [ Links ]

    6. Bocci V. Ozone as a biorregulator: Pharmacology and toxicology of ozonotheraphy. J Biol Reg 1997;31(10): 213. [ Links ]

    7. Borrego A, Zamora ZB, González R, Romay C, Menéndez S, Hernández F, et al. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats. Mediators of Inflammation 2004;13(1):13-9. [ Links ]

    8. Buckley RD, Hackney JD, Clark K, Posin C. Ozone and human blood. Arch Environ Health 1975;30:40-3. [ Links ]

    9. Calunga JL, Zamora ZB, Borrego A, Del Río S, Barber E, Menéndez S, et al. Ozone Therapy on Rats Submitted to Subtotal Nephrectomy: Role of Antioxidant System. Mediators of Inflammation 2005;4:221-7. [ Links ]

    10. Calunga JL, Menéndez S, Barber E, Merino N, Cruz E. Ozone biological response in kidneys of rats submitted to warm ischemia. Ozone-Sci Eng 2003;25(3):233-40. [ Links ]

    11. Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, et al. Effect of Ozone Therapy on Muscle Oxygenation. The journal of alternative and complementary medicine 2003;9(2):251-6. [ Links ]

    12. Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, et al. Ozone Therapy on Cerebral Blood Flow: A Preliminary Report. Evidence-based Complementary and Alternative Medicine 2004;1(3):315-9. [ Links ]

    13. Clavo B, Ruiz A, Lloret M, López L, Suárez G, Macías D, Rodríguez V, et al. Adjuvant Ozonetherapy in Advanced Head and Neck Tumors: A Comparative Study. Evidence-based Complementary and Alternative Medicine 2004;1(3)321-5. [ Links ]

    14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, U.S. Department of Health, Education, and Welfare. 1976. [ Links ]

    15. Hernández-Rosales FA, Calunga-Fernández JL, Turrent-Figueras J, Menéndez-Cepero S, Montenegro-Perdomo A. Ozone therapy effects on blood biomarkers and lung function in asthma. Arch Medical Res 2005;36(5):549-54. [ Links ]

    16. Hussam H, Ajamieh H, Berlanga J, Merino N, Sánchez G M, Carmona A M, Cepero S M, Giuliani A, Re L, León O S. Role of protein synthesis in the protection conferred by ozone-oxidative-preconditioning in hepatic ischaemia/reperfusión. Transplant International 2005;18(5):604-12. [ Links ]

    17. Jacobs M-T. Untersuchung Über Zwischenfalle Und Typische Komplikationen In Der Ozon-Sauerstoff-Therapie. Ozo Nachrichten 1982;1:5. [ Links ]

    18. Martínez-Sánchez G, Al-Dalain SM, Menéndez S, Re L, Giuliani A, Candelario-Jalil E, et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol 2005;523:151-61. [ Links ]

    19. Pioro-Boisset M, Esdaile JM, Fitzcharles MA. Artritis Care Res 1996;9(1):13-7. [ Links ]

    20. Rivera J, González T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004;22:554-60. [ Links ]

    21. Rokitanski O, Rokitanski A, Steiner J, Trubel W, Viebahn R, Washüttl J. Die ozontherapie bei peripheren, arteriellen durchblutungs-störungen; klinik, biochemische und blutgasanalytische untersuchungen. Wasser IOA, Ozon-Weltkongress; Berlin, 1981:53-75. [ Links ]

    22. Royuela A, Macías JA. Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 1997;9:81-94. [ Links ]

    23. Sanz J, Perdigón AL, Vázquez C. Adaptación española del inventario para la depresión de Beck-II: 2. Propiedades psicométricas en la población general. Clínica y Salud 2003;14:249-80. [ Links ]

    24. Valacchi G, Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediators of Inflammation 2000;9:271-6. [ Links ]

    25. Viebahn-Hänsler R. Einfluss auf den erythrozytenstoffwechsel. In: Neck EG, Viebahn-Hänsler R, editors. Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg: Ecomed, 1999:1-15. [ Links ]

    26. Vilagut G, Ferrer M, Rajmil L, Rebollo P, et al. El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gaceta Sanitaria 2005;19:135-50. [ Links ]

    27. Verrazzo G, Coppola L, Luongo C. Hyperbaric oxygen, oxygen-ozone therapy, and reologic parameters on blood in patients with peripheral occlusive arterial disease. Andersen Hiperbar Med 1995;22:17-22. [ Links ]

    28. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72. [ Links ]